Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having proline substitution at position 34 and other substitution(s) as defined herein that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.
Abstract: Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering PYY or an agonist thereof and GLP-1 or an agonist thereof to the subject, simultaneously or sequentially, thereby decreasing the calorie intake of the subject.
Type:
Application
Filed:
September 23, 2011
Publication date:
February 16, 2012
Inventors:
Michael Cowley, Roger Cone, Malcolm James Duncan Low, Andrew Butler, Stephen Robert Bloom, Caroline Jane Small, Rachel Louise Batterham, Mohammad Ali Ghatei
Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having at least one unnatural amino acid substitution, such as 4Hyp at position 34, that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.
Type:
Application
Filed:
February 19, 2010
Publication date:
February 16, 2012
Inventors:
Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira
Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
Type:
Application
Filed:
May 2, 2011
Publication date:
December 15, 2011
Applicant:
Bristol-Myers Squibb Company
Inventors:
Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
Abstract: Neuromedin U receptor agonists for use in the treatment of metabolic disorders such as obesity and diabetes are disclosed. In particular, disclosed are neuromedin U receptor agonists that comprise neuromedin S (NMS).
Type:
Application
Filed:
September 17, 2008
Publication date:
December 8, 2011
Inventors:
Donald J. Marsh, Antonello Pessi, Elisabetta Bianchi, Paolo Ingallinella, Andrea Peier, Alessandro Pocai
Abstract: The present invention relates to a PYY or PP peptide derivative or analogue thereof derivatised with one or more serum albumin binding side chains comprising a dis-tal tetrazole or carboxylic acid group. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y receptor modulation.
Type:
Application
Filed:
May 18, 2009
Publication date:
November 10, 2011
Applicant:
Novo Nordisk A/S
Inventors:
Søren Østergaard, Sanne Møller Knudsen, Jane Spetzler, Rasmus Jørgensen, Jacob Kofoed
Abstract: The present invention relates to methods and products for the treatment of obesity. The invention discloses a method of treating obesity related disease in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a composition which causes the continued down regulation of the NPY-1 or NPY-5 receptor.
Abstract: The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The composition of the present invention facilitates the delivery of PYY, a PYY agonist, or a mixture thereof and increases its bioavailability compared to administration without the delivery agent compound. PPY and PYY agonists possess activity as agents to reduce nutrient availability, including reduction of food intake.
Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
Type:
Application
Filed:
March 25, 2011
Publication date:
July 14, 2011
Inventors:
Karin Conde-Knape, Waleed Danho, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Jefferson Wright Tilley
Abstract: Disclosed are drug delivery systems for the delivery of small molecule and macromolecular drugs. More particularly, disclosed are substituted analogs of 3,6-di(alkyl-4 aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromolecular drugs including therapeutic, prophylactic and diagnostic agents, stabilizing agents and systems for their delivery.
Abstract: A transdermal patch formulation of a viscous liquid that includes an active agent of incretin or incretin mimetic peptide, a stabilizer, a buffer, a water soluble thickening agent, and a pharmaceutically acceptable carrier. Also, a patch adapted for transdermal delivery of the active agent and having a drug reservoir compartment of the transdermal patch formulation and a system for facilitating transdermal delivery of the active agent through the skin of a subject. The system includes the patch and an apparatus capable of generating a plurality of micro-channels in an area on the subject's skin. The patch and apparatus are used in methods of treatment for reducing blood glucose level, lowering plasma glucagon levels, reducing food intake, or reducing gastric motility in a subject in need of the same by extending the release of the incretin or incretin mimetic peptide in the subject.
Type:
Application
Filed:
July 21, 2009
Publication date:
June 2, 2011
Applicant:
Transpharma Medical Ltd.
Inventors:
Keren Mevorat-Kaplan, Galit Levin, Hagit Sacks, Meir Stern
Abstract: The present invention relates to compositions and methods for use in the prevention or treatment of excess weight in a mammal. The compositions comprise oxyntomodulin which is shown to reduce food intake and/or increase energy expenditure.
Type:
Application
Filed:
September 3, 2010
Publication date:
January 27, 2011
Applicant:
IMPERIAL INNOVATIONS LIMITED
Inventors:
Stephen Robert Bloom, Mohammad Ali Ghatei, Caroline Jane Small, Catherine Louise Dakin
Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
Type:
Application
Filed:
June 3, 2010
Publication date:
January 6, 2011
Inventors:
Craig A. Rosen, Adam Bell, Paul A. Moore, Yanggu Shi, David Lafleur, Jason B. Bock, Michael W. Laird, William A. Haseltine, Douglas B. Woods, Mani Subramanian
Abstract: The objective of the present invention is to provide a new antifeedant. The other objective of the present invention is to provide a NMU derivative showing a high antifeedant activity even in common administration forms such as peripheral administration. A neuromedin U derivative wherein a methoxypolyethylene glycol is bound via a linker having a specific structure to a polypeptide which contains at least 8 amino acids of the C-terminus of an amino acid sequence of neuromedin U and which consists of the same or substantially the same amino acid sequence as the amino acid sequence of neuromedin U.